Optimizing biologics for chronic plaque psoriasis: insights on non‐medical interruptions of IL‐17, IL‐12/23, and IL‐23 inhibitors

Although the overall effectiveness after interruption and resumption of treatment with secukinumab or ustekinumab was comparable, the time to achieve PASI 75 was longer following an interruption. Continuous, uninterrupted treatment with a given biologic is therefore recommended whenever possible.